%0 Journal Article %A Denton, Eve %A Hew, Mark %A Peters, Matthew J %A Upham, John W %A Bulathsinhala, Lakmini %A Tran, Trung N %A Martin, Neil %A Bergeron, Celine %A Al-Ahmad, Mona %A Altraja, Alan %A Larenas-Linnemann, Désirée %A Murray, Ruth %A Celis-Preciado, Carlos Andrés %A Al-Lehebi, Riyad %A Belhassen, Manon %A Bhutani, Mohit %A Bosnic-Anticevich, Sinthia Z %A Bourdin, Arnaud %A Brusselle, Guy G. %A Busby, John %A Canonica, Giorgio Walter %A Heffler, Enrico %A Chapman, Kenneth R %A Charriot, Jérémy %A Christoff, George C %A Chung, Li Ping %A García-Cosío, Borja %A Côté, Andréanne %A Costello, Richard W. %A Cushen, Breda %A Fingleton, James %A Fonseca, João A %A Gibson, Peter G %A Heaney, Liam G %A Huang, Erick Wan-Chun %A Iwanaga, Takashi %A Jackson, David J %A Koh, Mariko Siyue %A Lehtimäki, Lauri %A Máspero, Jorge %A Mahboub, Bassam %A Menzies-Gow, Andrew N %A Mitchell, Patrick D %A Papadopoulos, Nikolaos G %A Papaioannou, Andriana I %A Perez-de-Llano, Luis %A Perng, Diahn-Warng %A Pfeffer, Paul E %A Popov, Todor A %A Porsbjerg, Celeste M %A Rhee, Chin Kook %A Roche, Nicolas %A Sadatsafavi, Mohsen %A Salvi, Sundeep %A Schmid, Johannes M. %A Sheu, Chau-Chyun %A Sirena, Concetta %A Torres-Duque, Carlos A %A Salameh, Laila %A Patel, Pujan H %A Ulrik, Charlotte Suppli %A Wang, Eileen %A Wechsler, Michael E %A Price, David B %T Real-world biologics response and super-response in the International Severe Asthma Registry cohort %D 2024 %U https://hdl.handle.net/20.500.13003/20643 %X Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma.Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super-response criteria were: FEV1 increase by ≥500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day.5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, ~40-50% of initiators did not meet response criteria.Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria. %~